A biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
This is not a safe investment. However, the long term growth potential from its revolutionary new drug (Krystexxa) just cannot be overlooked. At an annual price of $59,000, if Krystexxa captures even a fraction of the estimated 5 million to 8 million U.S. gout patients, it could drive significant revenue for Savient.